Michael Hughes1, John D Pauling2,3, Andrew Moore4, Jennifer Jones5. 1. Department of Rheumatology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK. 2. Royal National Hospital for Rheumatic Disease, Bath, UK. 3. Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. 4. Musculoskeletal Research Unit, Bristol Medical School, University of Bristol, Bristol, UK. 5. Genetic Alliance UK, London, UK.
Abstract
Introduction: Outcomes related to Covid-19 in systemic sclerosis patients could be influenced by internal organ involvement and/or immunosuppressive treatment, leading to efforts to shield patients from Covid-19 transmission. We examined the impact of Covid-19 on the lived experience of systemic sclerosis with regards to other aspects of daily living including occupation and emotional well-being. Method: Individuals with systemic sclerosis or relatives/carers participated in an online survey, disseminated through international patient associations and social media pages, designed to examine the impact of Covid-19 on living with a rare disease. Results: Responses from 121 individuals (98% were patients with systemic sclerosis) from 14 countries were evaluable. Covid-19 was considered a probable/definite personal threat (93%) or threat for the individual they care for (100%). Approximately two-thirds of responders reported either cancellation or postponement/delay to appointments, diagnostic tests, medical therapies at home (e.g. infusions), surgery or transplant, psychiatry follow-up or rehabilitation services. Twenty-six percent reported at least one systemic sclerosis medicine/treatment had been unavailable, and 6% had to either stop taking usual medications or use an alternative. Most reported online consultations/telemedicine via phone (88%) and online (96%) as being 'fairly' or 'very' useful. Respondents reported tensions among family members (45%) and difficulty overcoming problems (48%). Restrictions on movement left around two-thirds feeling isolated (61%), unhappy and/or depressed (64%), although the majority (85%) reported a strengthening of the family unit. Conclusion: Covid-19 has resulted in significant impact on the clinical-care and emotional well-being of systemic sclerosis patients. Changes to clinical care delivery have been well-received by patients including telemedicine consultations.
Introduction: Outcomes related to Covid-19 in systemic sclerosis patients could be influenced by internal organ involvement and/or immunosuppressive treatment, leading to efforts to shield patients from Covid-19 transmission. We examined the impact of Covid-19 on the lived experience of systemic sclerosis with regards to other aspects of daily living including occupation and emotional well-being. Method: Individuals with systemic sclerosis or relatives/carers participated in an online survey, disseminated through international patient associations and social media pages, designed to examine the impact of Covid-19 on living with a rare disease. Results: Responses from 121 individuals (98% were patients with systemic sclerosis) from 14 countries were evaluable. Covid-19 was considered a probable/definite personal threat (93%) or threat for the individual they care for (100%). Approximately two-thirds of responders reported either cancellation or postponement/delay to appointments, diagnostic tests, medical therapies at home (e.g. infusions), surgery or transplant, psychiatry follow-up or rehabilitation services. Twenty-six percent reported at least one systemic sclerosis medicine/treatment had been unavailable, and 6% had to either stop taking usual medications or use an alternative. Most reported online consultations/telemedicine via phone (88%) and online (96%) as being 'fairly' or 'very' useful. Respondents reported tensions among family members (45%) and difficulty overcoming problems (48%). Restrictions on movement left around two-thirds feeling isolated (61%), unhappy and/or depressed (64%), although the majority (85%) reported a strengthening of the family unit. Conclusion: Covid-19 has resulted in significant impact on the clinical-care and emotional well-being of systemic sclerosis patients. Changes to clinical care delivery have been well-received by patients including telemedicine consultations.
Authors: Christopher P Denton; Michael Hughes; Nataliya Gak; Josephine Vila; Maya H Buch; Kuntal Chakravarty; Kim Fligelstone; Luke L Gompels; Bridget Griffiths; Ariane L Herrick; Jay Pang; Louise Parker; Anthony Redmond; Jacob van Laar; Louise Warburton; Voon H Ong Journal: Rheumatology (Oxford) Date: 2016-06-09 Impact factor: 7.580
Authors: Michael Hughes; John D Pauling; Jennifer Jones; Christopher P Denton; Robyn T Domsic; Tracy M Frech; Ariane L Herrick; Dinesh Khanna; Marco Matucci-Cerinic; Lorraine McKenzie; Lesley Ann Saketkoo; Rachael Gooberman-Hill; Andrew Moore Journal: Arthritis Care Res (Hoboken) Date: 2020-05 Impact factor: 4.794
Authors: Elizabeth Reilly; Sarah Skeoch; Sarah Hardcastle; John D Pauling; Megan Rowe; Tehseen Ahmed; Andrew Allard; Bashaar Boyce; Ellie Korendowych; Chloe Lapraik; William Tillett; Raj Sengupta Journal: Clin Med (Lond) Date: 2020-09-11 Impact factor: 2.659
Authors: Sandra Maximiano de Oliveira; Lucas Victória de Oliveira Martins; Ana Paula Lupino-Assad; Ana Cristina Medeiros-Ribeiro; Daniela Aparecida de Moraes; Ana Paula Toledo Del-Rio; Maria Carolina Oliveira; Percival Degrava Sampaio-Barros; Cristiane Kayser Journal: Semin Arthritis Rheum Date: 2022-02-25 Impact factor: 5.431
Authors: Anna-Maria Hoffmann-Vold; Oliver Distler; Cosimo Bruni; Christopher P Denton; Jeska de Vries-Bouwstra; Marco Matucci Cerinic; Madelon C Vonk; Armando Gabrielli Journal: Lancet Rheumatol Date: 2022-07-21